By Fineline Cube 
Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion protein, IBI363, has received Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE). The designation covers the treatment of advanced microsatellite stable or mismatch repair proficient (MSS/pMMR) colorectal cancer in patients who have failed at least two prior lines of standard systemic therapy, when administered in combination with bevacizumab.
Regulatory Milestone Details
| Parameter | Detail |
|---|---|
| Compound | IBI363 |
| Mechanism | First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein |
| New BTD Indication | Advanced MSS/pMMR colorectal cancer + bevacizumab |
| Patient Population | ≥2 prior lines of standard systemic therapy failed |
| Clinical Stage | Phase III study initiated in China |
| Regulatory Authority | Center for Drug Evaluation (CDE), China |
This marks the third Breakthrough Therapy Designation for IBI363 from Chinese regulators, complementing its existing regulatory momentum.
Comprehensive Regulatory Portfolio
- China CDE Breakthrough Therapy Designations: 3 total (including new colorectal cancer indication)
- U.S. FDA Fast Track Designations: 2 (covering non-small cell lung cancer and melanoma)
- Global Development Strategy: Parallel advancement in both U.S. and Chinese markets
The new BTD specifically addresses one of oncology’s most challenging patient populations—MSS/pMMR colorectal cancer patients who typically do not respond to conventional immunotherapy due to their “cold” tumor microenvironment.
Scientific & Clinical Significance
IBI363’s unique PD-1/IL-2α-bias bispecific design represents a novel approach to overcoming immune resistance mechanisms:
- Dual Mechanism: Simultaneously blocks PD-1 checkpoint inhibition while delivering biased IL-2α signaling to enhance T-cell activation
- Cold Tumor Targeting: Designed to convert immunologically “cold” tumors into “hot” tumors responsive to immunotherapy
- Combination Rationale: Paired with bevacizumab to modulate tumor vasculature and further enhance immune cell infiltration
- Unmet Need Focus: Addresses MSS/pMMR colorectal cancer, which represents approximately 85% of all colorectal cancer cases and lacks effective immunotherapy options
Market & Strategic Context
- Colorectal Cancer Burden: China accounts for nearly 30% of global colorectal cancer cases, with MSS/pMMR representing the majority of patients
- Competitive Differentiation: IBI363 is among the first bispecific antibodies specifically engineered to address immune resistance in cold tumors
- Pipeline Validation: Multiple regulatory designations across different tumor types validate the platform’s broad applicability
- Commercial Potential: Success in MSS/pMMR colorectal cancer would represent a significant market opportunity given the large patient population and limited treatment options
This latest BTD reinforces Innovent’s position as an innovator in next-generation bispecific antibody development and addresses critical gaps in immuno-oncology treatment paradigms.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory decisions, and competitive dynamics in the oncology space.-Fineline Info & Tech